Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 201

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results

Open access
Mahon, Jeffrey L, Sosenko, Jay M, Rafkin-Mervis, Lisa, Krause-Steinrauf, Heidi, Lachin, John M, Thompson, Clinton, Bingley, Polly J, Bonifacio, Ezio, Palmer, Jerry P, Eisenbarth, George S, Wolfsdorf, Joseph, Skyler, Jay S, the TrialNet Natural History Committee, Type 1 Diabetes TrialNet Study Group · 2009 · Pediatric Diabetes

Abstract

OBJECTIVES: TrialNet's goal to test preventions for type 1 diabetes has created an opportunity to gain new insights into the natural history of pre-type 1 diabetes. The TrialNet Natural History Study (NHS) will assess the predictive value of existing and novel risk markers for type 1 diabetes and will find subjects for prevention trials. RESEARCH DESIGN AND METHODS: The NHS is a three-phase, prospective cohort study. In phase 1 (screening), pancreatic autoantibodies (glutamic acid decarboxylase, insulin, ICA-512, and islet cell antibodies) are measured. Phase 2 (baseline risk assessment) includes oral glucose tolerance tests (OGTTs) in antibody-positive subjects and estimation of 5-yr diabetes risks according to the OGTT and number of confirmed positive antibody tests. Phase 3 (follow-up risk assessments) requires OGTTs every 6 months. In phases 2 and 3, samples are collected for future tests of T-lymphocyte function, autoantibody isotypes, RNA gene expression, and proteomics. The primary outcome is diabetes onset. RESULTS: Of 12 636 relatives screened between March 2004 and December 2006, 605 (4.8%) were positive for at least one biochemical antibody. Of these, 322 were confirmed antibody positive and completed phase 2, of whom 296 subjects were given preliminary 5-yr diabetes risks of <25% (n = 132), > or =25% (n = 36), and > or =50% (n = 128) where the latter two categories represent different subjects based on number of confirmed positive antibodies (2, > or =25%; 3 or more, > or =50%) and/or an abnormal OGTT (> or =50%). CONCLUSIONS: The NHS is identifying potential prevention trial subjects and is assembling a large cohort that will provide new natural history information about pre-type 1 diabetes. Follow-up to diabetes will help establish the biological significance and clinical value of novel type 1 diabetes risk markers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1399-5448.2008.00464.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 201

Metadata

Authors
Mahon, J. L., Sosenko, J. M., Rafkin-Mervis, L., Krause-Steinrauf, H., Lachin, J. M., Thompson, C., Bingley, P. J., Bonifacio, E., Palmer, J. P., Eisenbarth, G. S., Wolfsdorf, J., Skyler, J. S., the TrialNet Natural History Committee, & Type 1 Diabetes TrialNet Study Group
Venue
Pediatric Diabetes
Publisher
Wiley
Published
2009-03
Volume
10
Issue
2
Pages
97-104
ISSN
  • 1399-543X (ISSN-L)
  • 1399-5448
OpenAlex
W2043114954
Cited by
201
References
7
FWCI
4.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. https://app.cochat.ai/papers/10.1111/j.1399-5448.2008.00464.x
The paper
Mahon, J. L., Sosenko, J. M., Rafkin-Mervis, L., Krause-Steinrauf, H., Lachin, J. M., Thompson, C., Bingley, P. J., Bonifacio, E., Palmer, J. P., Eisenbarth, G. S., Wolfsdorf, J., Skyler, J. S., the TrialNet Natural History Committee, & Type 1 Diabetes TrialNet Study Group. (2009). The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatric Diabetes. https://doi.org/10.1111/j.1399-5448.2008.00464.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.